Oncology and Hematology

145-160 of 219

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice—Breast Cancer

  William J. Gradishar, MD; Erica L. Mayer, MD, MPH

  1.50 credits 10 episodes

  • 

    

    William J. Gradishar, MD

  • 

    

    Erica L. Mayer, MD, MPH

  • 

    

    Peter Schmid, FRCP, MD, PhD

  1.50 credits 10 episodes

• 

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  RestartResume

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  MinuteCE®

  First-line Treatment of MSI-H/dMMR mCRC: The Role of Immunotherapy

  Aparna R. Parikh, MD

  1.25 program credits

  • 

    

    Aparna R. Parikh, MD

  1.25 program credits

• 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  RestartResume

  Management of HR+, HER2- High-Risk EBC 

  MinuteCE®

  Management of HR+, HER2- High-Risk EBC 

  Erica L. Mayer, MD, MPH

  1.50 program credits

  • 

    

    Erica L. Mayer, MD, MPH

  1.50 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  Ignacio Duran, MD; Wenxin Xu, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  • 

    

    Wenxin Xu, MD

  1.25 program credits

• 

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  RestartResume

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  MinuteCE®

  Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances

  Susana Campos, MD, MPH; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  RestartResume

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  MinuteCE®

  Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances

  Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  RestartResume

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  MinuteCE®

  Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors

  Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  RestartResume

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  MinuteCE®

  Guideline Recommendations for Biomarker-Directed Therapies in Cervical Cancer

  Ritu Salani, MD; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Ritu Salani, MD

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into a Targeted Therapy Approach for Patients With Platinum-Resistant Ovarian Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  RestartResume

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  MinuteCE®

  Targeted Therapy in the Treatment of Recurrent Platinum-Resistant Ovarian Cancer

  Ritu Salani, MD; Nicoletta Colombo, MD

  1.00 program credit

  • 

    

    Ritu Salani, MD

  • 

    

    Nicoletta Colombo, MD

  1.00 program credit

• 

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  RestartResume

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  MinuteCE®

  First-Line Maintenance Therapy Using PARP Inhibitors for Ovarian Cancer

  Nicoletta Colombo, MD; Ritu Salani, MD

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  RestartResume

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  MinuteCE®

  Implementing Guideline-Concordant Care Into the Management of Frontline Patients With Recurrent Endometrial Cancer

  Ritu Salani, MD; Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Ritu Salani, MD

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  RestartResume

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  MinuteCE®

  Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer

  Nicoletta Colombo, MD; Susana Campos, MD, MPH

  1.00 program credit

  • 

    

    Nicoletta Colombo, MD

  • 

    

    Susana Campos, MD, MPH

  1.00 program credit

• 

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  RestartResume

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  MinuteCE®

  Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer

  Susana Campos, MD, MPH; Ritu Salani, MD

  1.00 program credit

  • 

    

    Susana Campos, MD, MPH

  • 

    

    Ritu Salani, MD

  1.00 program credit

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  Sandy Srinivas, MD

  1.25 program credits

  • 

    

    Sandy Srinivas, MD

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  Ignacio Duran, MD

  1.25 program credits

  • 

    

    Ignacio Duran, MD

  1.25 program credits

• Previous
• 1
• 2
• …
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• Next